Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Rese...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Stroke (1970) Jg. 51; H. 5; S. 1546
Hauptverfasser:	Giugliano, Robert P, Pedersen, Terje R, Saver, Jeffrey L, Sever, Peter S, Keech, Anthony C, Bohula, Erin A, Murphy, Sabina A, Wasserman, Scott M, Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.05.2020
Schlagworte:	peripheral arterial disease C-reactive protein stroke evolocumab proprotein convertase 9
ISSN:	1524-4628, 1524-4628
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!